Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial comparing efficacy and safety of paclitaxel oral solution (RMX3001) with paclitaxel injection (Taxol®) in patients with advanced gastric cancer who failed previous treatment

Next Previous
Trial Profile

A phase 3 trial comparing efficacy and safety of paclitaxel oral solution (RMX3001) with paclitaxel injection (Taxol®) in patients with advanced gastric cancer who failed previous treatment

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 13 Sep 2022 According to a HaiHe Biopharma media release, Marketing Authorization Application (MAA) for Paclitaxel Oral Solution (RMX3001) in gastric cancer (GC) has been accepted for review by the National Medical Products Administration-Center for Drug Evaluation (NMPA-CDE).
  • 13 Sep 2022 According to a HaiHe Biopharma media release, Professor Jin Li from Shanghai East Hospital and Professor Shukui Qin from Nanjing Jinling Hospital is the leading principal investigator of this study.
  • 13 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top